Emcure Pharma to Distribute Novo Nordisk’s Poviztra in India
Filing Summary
Emcure Pharmaceuticals Ltd has entered into a strategic partnership with Novo Nordisk India to distribute and commercialize Poviztra, a semaglutide injection 2.4 mg, in India. This collaboration marks Emcure as the first Indian company with exclusive rights to market Poviztra, a second brand of Wegovy, for weight loss. The partnership aims to enhance the distribution and marketing reach of semaglutide, particularly in regions beyond Novo Nordisk’s current coverage. Emcure will handle the commercialization and marketing responsibilities, expanding access to this treatment for individuals with obesity and overweight conditions.
Emcure Pharmaceuticals Ltd has announced a strategic partnership with Novo Nordisk India to distribute and commercialize Poviztra, a semaglutide injection 2.4 mg, in India. This agreement positions Emcure as the first Indian company with exclusive rights to market Poviztra, a second brand of Wegovy, for weight loss. The collaboration is part of Novo Nordisk’s efforts to make its semaglutide molecule accessible to a larger population in India, particularly those living with overweight and obesity.
The financial terms of the agreement have not been disclosed. However, Emcure will be responsible for the exclusive distribution and commercialization of Poviztra in India. This partnership is expected to enhance the availability of semaglutide for weight management, expanding its reach beyond the regions currently served by Novo Nordisk India. The collaboration aims to broaden access to high-quality, safe, and effective weight management medication in the Indian market.
Operationally, Emcure will focus on the distribution and marketing of Poviztra, ensuring its availability through pharmacies across India. The semaglutide injection is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management. It is also used to reduce the risk of major adverse cardiovascular events in individuals with obesity or overweight conditions. Poviztra is available in a once-weekly pen device, offering convenience and precise dosing.
The timeline for the implementation of this partnership has not been specified in the filing. However, Wegovy, the original brand of semaglutide injection 2.4 mg, was launched in India in June 2025. The introduction of Poviztra as a second brand aims to further expand the reach of this treatment in the Indian market.
The partnership involves Novo Nordisk India and Emcure Pharmaceuticals Ltd. Novo Nordisk India will provide the semaglutide molecule, while Emcure will handle the distribution and marketing responsibilities. This collaboration combines Novo Nordisk’s innovation in GLP-1 therapies with Emcure’s marketing and distribution capabilities to improve access to obesity treatment in India.
The market context highlights the significant prevalence of obesity in India, with nearly 254 million people living with generalized obesity and another 351 million with abdominal obesity. The partnership aims to address the unmet medical needs associated with obesity, providing effective treatment solutions. The introduction of Poviztra is part of a broader effort to ensure innovative treatments reach a greater number of patients in India.
Novo Nordisk India is a subsidiary of Novo Nordisk A/S, a global healthcare company focused on defeating serious chronic diseases such as diabetes and obesity. The company is committed to pioneering scientific breakthroughs and expanding access to its medicines.
Emcure Pharmaceuticals Ltd is a leading Indian pharmaceutical company engaged in developing, manufacturing, and marketing a broad range of pharmaceutical products. The company is known for its commitment to innovation and quality, focusing on improving patient health across several major therapeutic areas.